How will this database improve Asian cancer patient diagnosis?

Question

Accepted Answer

This database will enhance the precision of diagnoses for Asian cancer patients by revealing specific genetic characteristics of their cancers.

This comprehensive genetic and genomic database, developed by Malaysian scientists in collaboration with the University of Cambridge, provides unprecedented insight into the molecular underpinnings of Asian breast cancers. By mapping the genomes of 1,000 breast cancer patients, the initiative significantly boosts Asian representation in genomic research, which was previously dominated by Caucasian genomes. This enhanced understanding allows for more accurate identification of cancer subtypes and genetic alterations, enabling a tailored approach to diagnosis and treatment.
Discovery of Aggressive Cancer Subtypes

The genomic map has revealed that Asian individuals are more prone to specific aggressive forms of breast cancer, notably HER2-positive subtypes. Patients with HER2-positive breast cancers experience a significantly lower overall survival rate compared to other subtypes. Understanding this predisposition is crucial for early and accurate diagnosis, as it signals a potentially more challenging disease course that requires specific therapeutic strategies.
Identification of High-Risk Gene Mutations

This research has also highlighted a higher likelihood of TP53 gene mutations among Asian breast cancer patients, with approximately one in three affected. Cancers harbouring TP53 mutations are generally associated with poorer survival outcomes. The database facilitates the identification of these specific mutations, which is vital for diagnosis, as there are currently no targeted treatments for these particular cancer types, necessitating further research and development.
Understanding Immune Cell Interactions

The study has shown that Asian breast cancers are more likely to exhibit active immune cells compared to European cancers. This finding has already spurred the initiation of a new clinical trial, Auror, designed to test the efficacy of immunotherapy in Asian breast cancer patients. Furthermore, the database has identified the genetic marker APOBEC3B as being four times more prevalent in Asians, contributing to breast cancers being surrounded by immune cells that fail to recognise them as cancerous. This insight is driving clinical trials aimed at reactivating the immune system to improve treatment responses in patients with metastatic breast cancer.

Reading history

Hide →

This history is cleared when the page is closed.

How will this database improve Asian cancer patient diagnosis?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends